Last edition
News about "MedImpact to Launch Affordable Unbranded Biosimila"
MedImpact to Launch Affordable Unbranded Biosimilar Ustekinumab-aekn in 2026
With specialty drug costs rising and many pharmacies closing, MedImpact’s strategy introduces a new sourcing model that provides pharmacies with access to lower prices while giving payers more flexibility and control over healthcare expenses. Importantly, this approach will extend beyond MedImpact’s own clients, offering broader industry-wide benefits.
MedImpact To Launch Affordable Unbranded Biosimila | 20/08/2025 | By Darshana | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy